litlas
Log inCreate account

Richard Marais

Active 1989–2024

132
Papers
46,373
Citations
100
h-index
131
i10-index

Citations

Citations per year for Richard Marais1971: 1 citations1990: 14 citations1991: 34 citations1992: 46 citations1993: 63 citations1994: 109 citations1995: 145 citations1996: 131 citations1997: 130 citations1998: 133 citations1999: 182 citations2000: 162 citations2001: 184 citations2002: 204 citations2003: 281 citations2004: 278 citations2005: 400 citations2006: 403 citations2007: 447 citations2008: 438 citations2009: 441 citations2010: 609 citations2011: 629 citations2012: 714 citations2013: 652 citations2014: 639 citations2015: 567 citations2016: 548 citations2017: 578 citations2018: 552 citations2019: 1,314 citations2020: 1,452 citations2021: 1,284 citations2022: 1,055 citations2023: 837 citations2024: 1,231 citations2025: 562 citations2026: 23 citations1972–1989: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,633 citing papers, 30.4% of this breakdownChina: 1,740 citing papers, 9.4% of this breakdownUnited Kingdom: 1,545 citing papers, 8.3% of this breakdownGermany: 1,028 citing papers, 5.5% of this breakdownItaly: 881 citing papers, 4.8% of this breakdownFrance: 785 citing papers, 4.2% of this breakdownAustralia: 648 citing papers, 3.5% of this breakdownJapan: 564 citing papers, 3% of this breakdownCanada: 496 citing papers, 2.7% of this breakdownNetherlands: 486 citing papers, 2.6% of this breakdownSpain: 482 citing papers, 2.6% of this breakdownSwitzerland: 401 citing papers, 2.2% of this breakdown
0%30.4%Other 20.8%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology52.9%
  • Medicine36.3%
  • Immunology and Microbiology4.9%
  • Neuroscience1.4%
  • Computer Science1.1%
  • Engineering0.9%
  • Other2.5%

Topics

  • Melanoma and MAPK Pathways8.3%
  • Cancer Immunotherapy and Biomarkers3.2%
  • Protein Kinase Regulation and GTPase Signaling3.1%
  • Cancer Genomics and Diagnostics2.8%
  • Cutaneous Melanoma Detection and Management2.6%
  • Immunotherapy and Immune Responses2.2%
  • Other77.8%

Coauthors

All papers

Open in search
  1. Mutations of the BRAF gene in human cancer

    Authors: Helen Davies, Graham R. Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon W. Teague, Hayley Woffendin, Mathew J. Garnett, William Bottomley, Neil M. Davis, Ed Dicks, Rebecca Ewing, Yvonne Floyd, Kristian Gray, Sarah Hall, Rachel Hawes, Jaime Hughes, Vivian Kosmidou, Andrew Menzies, Catherine Mould, Adrian G. Parker, Claire Stevens, Stephen Watt, Steven Hooper, Rebecca Wilson, Hiran Jayatilake, Barry A. Gusterson, Colin Cooper, Janet Shipley, Darren Hargrave, Katherine Pritchard-Jones, Norman J. Maitland, Georgia Chenevix‐Trench, Gregory J. Riggins, Darell D. Bigner, Giuseppe Palmieri, Antonio Cossu, Adrienne M. Flanagan, Andrew G. Nicholson, Judy Ho, Suet Yi Leung, Siu Tsan Yuen, Barbara L. Weber, Hilliard F. Seigler, Timothy L. Darrow, Hugh Paterson, Richard Marais, Christopher J. Marshall, Richard Wooster, Michael R. Stratton, P. Andrew Futreal - Nature 2002 cited by 10,737

  2. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma

    Authors: Karla A. Lee, Andrew Maltez Thomas, Laura A. Bolte, Johannes R. Björk, Laura Kist de Ruijter, Federica Armanini, Francesco Asnicar, Aitor Blanco‐Míguez, Ruth Board, Neus Calbet‐Llopart, Lisa Derosa, Nathalie Dhomen, Kelly Brooks, Mark Harland, Mark Harries, Emily R. Leeming, Paul Lorigan, Paolo Manghi, Richard Marais, Julia Newton‐Bishop, Luigi Nezi, Federica Pinto, Míriam Potrony, Susana Puig, Patricio Serra-Bellver, Heather M. Shaw, Sabrina Tamburini, Sara Valpione, Amrita Vijay, Levi Waldron, Laurence Zitvogel, Moreno Zolfo, Elisabeth G.E. de Vries, Paul Nathan, Rudolf S.N. Fehrmann, Véronique Bataille, Geke A.P. Hospers, Tim D. Spector, Rinse K. Weersma, Nicola Segata - Nature Medicine 2022 cited by 429

  3. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity

    Authors: Santiago Zelenay, Annemarthe G. van der Veen, Jan P. Böttcher, Kathryn J. Snelgrove, Neil C. Rogers, Sophie E. Acton, Probir Chakravarty, María Romina Girotti, Richard Marais, Sergio A. Quezada, Erik Sahai, Caetano Reis e Sousa - Cell 2015 cited by 1,123

  4. Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity

    Authors: Colin Hutton, Felix Heider, Adrián Blanco‐Gómez, Antonia Banyard, Alexander Kononov, Xiaohong Zhang, Saadia A. Karim, Viola Paulus-Hock, Dale M. Watt, Nina G. Steele, Samantha B. Kemp, Elizabeth Hogg, Joanna Kelly, Rene-Filip Jackstadt, Filipa M. Lopes, Matteo Menotti, Luke Chisholm, Ángela Lamarca, Juan W. Valle, Owen J. Sansom, Caroline J. Springer, Angeliki Malliri, Richard Marais, Marina Pasca di Magliano, Santiago Zelenay, Jennifer P. Morton, Claus Jørgensen - Cancer Cell 2021 cited by 323

  5. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

    Authors: Paul Wan, Mathew J. Garnett, S. Mark Roe, Sharlene Lee, Dan Niculescu‐Duvaz, Valerie M. Good, Cancer Genome Project, Chris M. Jones, Christopher J. Marshall, Caroline J. Springer, David Barford, Richard Marais - Cell 2004 cited by 2,815

  6. Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma

    Authors: Johannes R. Björk, Laura A. Bolte, Andrew Maltez Thomas, Karla A. Lee, Niccolò Rossi, Thijs T. Wind, Lotte M. Smit, Federica Armanini, Francesco Asnicar, Aitor Blanco‐Míguez, Ruth Board, Neus Calbet‐Llopart, Lisa Derosa, Nathalie Dhomen, Kelly Brooks, Mark Harland, Mark Harries, Paul Lorigan, Paolo Manghi, Richard Marais, Julia Newton‐Bishop, Luigi Nezi, Federica Pinto, Míriam Potrony, Susana Puig, Patricio Serra-Bellver, Heather M. Shaw, Sabrina Tamburini, Sara Valpione, Levi Waldron, Laurence Zitvogel, Moreno Zolfo, Elisabeth G.E. de Vries, Paul Nathan, Rudolf S.N. Fehrmann, Tim D. Spector, Véronique Bataille, Nicola Segata, Geke A.P. Hospers, Rinse K. Weersma - Nature Medicine 2024 cited by 124

  7. The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival

    Authors: Sara Valpione, Piyushkumar A. Mundra, Elena Galvani, L Campana, Paul Lorigan, Francesco De Rosa, Avinash Gupta, John Weightman, Sarah Mills, Nathalie Dhomen, Richard Marais - Nature Communications 2021 cited by 193

  8. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations

    Authors: Curtis H. Kugel, Stephen M. Douglass, Marie R. Webster, Amanpreet Kaur, Qin Liu, Xiangfan Yin, Sarah A. Weiss, Farbod Darvishian, Rami N. Al‐Rohil, Abibatou Ndoye, Reeti Behera, Gretchen M. Alicea, Brett L. Ecker, Mitchell E. Fane, Michael J. Allegrezza, Nikolaos Svoronos, Vinit Kumar, Daniel Wang, Rajasekharan Somasundaram, Siwen Hu‐Lieskovan, Alpaslan Özgün, Meenhard Herlyn, José R. Conejo-García, Dmitry I. Gabrilovich, Erica L. Stone, Theodore S. Nowicki, Jeffrey A. Sosman, Rajat Rai, Matteo S. Carlino, Georgina V. Long, Richard Marais, Antoni Ribas, Zeynep Eroglu, Michael A. Davies, Bastian Schilling, Dirk Schadendorf, Wei Xu, Ravi K. Amaravadi, Alexander M. Menzies, Jennifer L. McQuade, Douglas B. Johnson, Iman Osman, Ashani T. Weeraratna - Clinical Cancer Research 2018 cited by 361

  9. Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling

    Authors: Eishu Hirata, María Romina Girotti, Amaya Virós, Steven Hooper, Bradley Spencer‐Dene, Michiyuki Matsuda, James Larkin, Richard Marais, Erik Sahai - Cancer Cell 2015 cited by 572

  10. The journey from melanocytes to melanoma

    Authors: Patricia P. Centeno, Valeria Pavet, Richard Marais - Nature reviews. Cancer 2023 cited by 181

  11. Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy

    Authors: Sara Valpione, Elena Galvani, Joshua Tweedy, Piyushkumar A. Mundra, Antonia Banyard, Philippa Middlehurst, Jeff Barry, Sarah Mills, Zena Salih, John Weightman, Avinash Gupta, Gabriela Gremel, Franziska Baenke, Nathalie Dhomen, Paul Lorigan, Richard Marais - Nature Cancer 2020 cited by 231

  12. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

    Authors: Sonja J. Heidorn, Carla Milagre, Steven R. Whittaker, Arnaud Nourry, Ion Niculescu-Duvas, Nathalie Dhomen, Jahan Hussain, Jorge S. Reis‐Filho, Caroline J. Springer, Catrin Pritchard, Richard Marais - Cell 2010 cited by 1,474

  13. Melanoma models for the next generation of therapies

    Authors: E. Elizabeth Patton, Kristen L. Mueller, David J. Adams, Niroshana Anandasabapathy, Andrew E. Aplin, Corine Bertolotto, Marcus Bosenberg, Craig J. Ceol, Christin E. Burd, Ping Chi, Meenhard Herlyn, Sheri L. Holmen, Florian A. Karreth, Charles K. Kaufman, Shaheen Khan, Sebastian Kobold, Eleonora Leucci, Carmit Levy, David B. Lombard, Amanda W. Lund, Kerrie L. Marie, Jean‐Christophe Marine, Richard Marais, Martin McMahon, Carla Daniela Robles‐Espinoza, Ze’ev A. Ronai, Yardena Samuels, Marı́a S. Soengas, Jessie Villanueva, Ashani T. Weeraratna, Richard M. White, Iwei Yeh, Jiyue Zhu, Leonard I. Zon, Marc Hurlbert, Glenn Merlino - Cancer Cell 2021 cited by 227

  14. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA

    Authors: Lavinia Tan, Shahneen Sandhu, Rebecca Lee, James Li, Jason Callahan, Sarah Ftouni, Nathalie Dhomen, Philippa Middlehurst, Andrea Wallace, Jeanette Raleigh, Athena Hatzimihalis, Michael A. Henderson, Mark Shackleton, Andrew Haydon, Victoria Mar, David Gyorki, D. Oudit, Mark A. Dawson, Rodney J. Hicks, Paul Lorigan, Grant A. McArthur, Richard Marais, Stephen Q. Wong, Sarah‐Jane Dawson - Annals of Oncology 2019 cited by 190

  15. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study

    Authors: Dominic G. Rothwell, Mahmood Ayub, Natalie Cook, Fiona Thistlethwaite, Louise Carter, Emma Dean, Nigel Smith, Shaun Villa, Joanne Dransfield, Alexandra Clipson, Daniel J. White, Kamrun Nessa, Saba Ferdous, M. Howell, Avinash Gupta, Bedirhan Kilerci, Sumitra Mohan, Kris Frese, Sakshi Gulati, Crispin Miller, Allan M. Jordan, Helen Eaton, Nicholas Hickson, Ciara O’Brien, Donna M. Graham, Claire Kelly, S. Aruketty, Robert Metcalf, Jaseela Chiramel, Nadina Tinsley, Alexander J. Vickers, R Kurup, Hannah Frost, Julie Stevenson, Siobhan Southam, Dónal Landers, Andrew J. Wallace, Richard Marais, Andrew Hughes, Ged Brady, Caroline Dive, Matthew Krebs - Nature Medicine 2019 cited by 306

  16. Melanoma biology and new targeted therapy

    Authors: Vanessa C. Gray‐Schopfer, Claudia Wellbrock, Richard Marais - Nature 2007 cited by 1,384

  17. SF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma

    Authors: Simon J. Furney, Malin Pedersen, David Gentien, Amaury G. Dumont, Audrey Rapinat, Laurence Desjardins, Samra Turajlic, Sophie Piperno‐Neumann, Pierre de la Grange, Sergio Roman‐Roman, Marc‐Henri Stern, Richard Marais - Cancer Discovery 2013 cited by 434

  18. The RAF proteins take centre stage

    Authors: Claudia Wellbrock, Maria Karasarides, Richard Marais - Nature Reviews Molecular Cell Biology 2004 cited by 1,207

  19. The role of signaling pathways in the development and treatment of hepatocellular carcinoma

    Authors: Steven R. Whittaker, Richard Marais, Andrew X. Zhu - Oncogene 2010 cited by 823

  20. ROCK and JAK1 Signaling Cooperate to Control Actomyosin Contractility in Tumor Cells and Stroma

    Authors: Victoria Sanz‐Moreno, Cédric Gaggioli, Maggie Yeo, Jean Albrengues, Fredrik Wållberg, Amaya Virós, Steven Hooper, Richard Mitter, Chloé C. Féral, Martin Cook, James Larkin, Richard Marais, Guerrino Meneguzzi, Erik Sahai, Chris Marshall - Cancer Cell 2011 cited by 401

  21. Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy

    Authors: Bryan W. Miller, Jennifer P. Morton, Mark Pinese, Grazia Saturno, Nigel B. Jamieson, Ewan J. McGhee, Paul Timpson, Joshua D.G. Leach, Lynn McGarry, Emma Shanks, Peter J. Bailey, David K. Chang, Karin A. Oien, Saadia A. Karim, Amy Au, Colin W. Steele, Christopher Ross Carter, Colin J. McKay, Kurt I. Anderson, T.R. Jeffry Evans, Richard Marais, Caroline J. Springer, Andrew V. Biankin, Janine T. Erler, Owen J. Sansom - EMBO Molecular Medicine 2015 cited by 266

  22. Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma

    Authors: Rebecca Lee, Gabriela Gremel, Andrea Marshall, Kevin A. Myers, Nita Fisher, Janet Dunn, Nathalie Dhomen, Pippa Corrie, Mark R. Middleton, Paul Lorigan, Richard Marais - Annals of Oncology 2017 cited by 159

  23. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

    Authors: Michael P. Smith, Holly Brunton, Emily J. Rowling, Jennifer Ferguson, Imanol Arozarena, Zsofia Miskolczi, Jessica Lee, María Romina Girotti, Richard Marais, Mitchell P. Levesque, Reinhard Dummer, Dennie T. Frederick, Keith T. Flaherty, Zachary A. Cooper, Jennifer A. Wargo, Claudia Wellbrock - Cancer Cell 2016 cited by 251

  24. The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNFα

    Authors: Michael P. Smith, Berta Sanchez‐Laorden, Kate O’Brien, Holly Brunton, Jennifer Ferguson, Helen L. Young, Nathalie Dhomen, Keith T. Flaherty, Dennie T. Frederick, Zachary A. Cooper, Jennifer A. Wargo, Richard Marais, Claudia Wellbrock - Cancer Discovery 2014 cited by 209